Analysts See $-0.51 EPS for Quotient Limited (QTNT)

May 18, 2018 - By Cecil Scoggins

Quotient Limited (NASDAQ:QTNT) LogoInvestors sentiment increased to 1.93 in Q4 2017. Its up 0.51, from 1.42 in 2017Q3. It improved, as 5 investors sold Quotient Limited shares while 10 reduced holdings. 7 funds opened positions while 22 raised stakes. 30.23 million shares or 41.49% more from 21.37 million shares in 2017Q3 were reported.
Ameritas Ptnrs holds 2,347 shares. Park West Asset Mgmt Limited Liability holds 300,087 shares or 0.07% of its portfolio. American Intl Grp owns 0% invested in Quotient Limited (NASDAQ:QTNT) for 18,011 shares. Tiaa Cref Invest Ltd Limited Liability Company reported 0% stake. Lombard Odier Asset Mgmt (Usa) Corporation reported 151,777 shares or 0.06% of all its holdings. Clearbridge Limited Liability Corporation holds 0.26% or 2.56 million shares in its portfolio. Legal General Public Ltd holds 0% or 3,914 shares. Royal National Bank Of Canada, Ontario – Canada-based fund reported 2,022 shares. Macquarie Grp Ltd invested in 6,000 shares. Northern Tru Corporation invested in 235,893 shares. Hudson Bay Cap Mngmt L P, New York-based fund reported 480,000 shares. Ameriprise Finance reported 2.15M shares. Geode Mgmt Ltd Limited Liability Company holds 0% or 75,232 shares. Jpmorgan Chase &, a New York-based fund reported 5,768 shares. Highbridge Capital Mgmt Ltd Liability Corporation holds 2.28 million shares.

Since February 21, 2018, it had 1 insider buy, and 0 insider sales for $51,348 activity.

Analysts expect Quotient Limited (NASDAQ:QTNT) to report $-0.51 EPS on May, 28.They anticipate $0.18 EPS change or 26.09 % from last quarter’s $-0.69 EPS. After having $-0.47 EPS previously, Quotient Limited’s analysts see 8.51 % EPS growth. The stock increased 15.35% or $0.72 during the last trading session, reaching $5.41. About 1.15M shares traded or 272.94% up from the average. Quotient Limited (NASDAQ:QTNT) has declined 24.44% since May 18, 2017 and is downtrending. It has underperformed by 35.99% the S&P500.

Quotient Limited, a commercial-stage diagnostics company, develops, makes, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company has market cap of $246.63 million. The firm is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. It currently has negative earnings. It also develops, makes, and commercializes conventional reagent products for blood grouping, including antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping.

More important recent Quotient Limited (NASDAQ:QTNT) news were published by: Streetinsider.com which released: “Pre-Open Movers 05/18: (QTNT) (AFSI) (CERN) Higher; (AGRX) (ARQL) (CPB) Lower (more…)” on May 18, 2018, also Globenewswire.com published article titled: “Quotient Limited to Report Fourth Quarter and Fiscal Full Year 2018 Financial Results and Host Conference Call”, Streetinsider.com published: “Quotient (QTNT) Commences EU Blood Grouping Field Trial” on May 17, 2018. More interesting news about Quotient Limited (NASDAQ:QTNT) was released by: Nasdaq.com and their article: “Quotient Limited Reports Commencement of EU Blood Grouping Field Trial” with publication date: May 17, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: